BRUKER CORPORATION (BRKR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.20B USD | Liabilities, Current |
| Cash and equivalents | 184.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 545.90M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.12B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.20B | $184.90M | (m) | $545.90M | $1.12B | (m) |
| 2026-03-31 | (m) | $1.36B | $133.40M | (m) | $542.70M | $1.12B | (m) |
| 2025-12-31 | (m) | $1.28B | $298.80M | (m) | $544.90M | $1.09B | (m) |
| 2025-09-30 | (m) | $1.27B | $293.10M | (m) | $550.90M | $1.20B | (m) |
| 2025-06-30 | (m) | $1.35B | $92.00M | (m) | $522.60M | $1.22B | (m) |
| 2025-03-31 | (m) | $1.34B | $184.20M | (m) | $537.80M | $1.12B | (m) |
| 2024-12-31 | (m) | $1.28B | $183.40M | (m) | $565.50M | $1.07B | (m) |
| 2024-09-30 | (m) | $1.32B | $148.10M | (m) | $538.40M | $1.22B | (m) |
| 2024-06-30 | (m) | $1.30B | $169.70M | (m) | $507.20M | $1.18B | (m) |
| 2024-03-31 | (m) | $1.18B | $340.10M | (m) | $475.40M | $1.06B | (m) |
| 2023-12-31 | (m) | $1.20B | $488.30M | (m) | $492.00M | $968.30M | (m) |
| 2023-09-30 | (m) | $1.07B | $363.60M | (m) | $485.40M | $916.00M | (m) |
| 2023-06-30 | (m) | $1.05B | $574.80M | (m) | $450.80M | $914.60M | (m) |
| 2023-03-31 | (m) | $1.05B | $597.90M | (m) | $471.70M | $858.80M | (m) |
| 2022-12-31 | (m) | $914.30M | $645.50M | (m) | $472.70M | $800.10M | (m) |
| 2022-09-30 | (m) | $864.60M | $626.20M | (m) | $421.30M | $749.50M | (m) |
| 2022-06-30 | (m) | $818.40M | $723.00M | (m) | $402.60M | $759.00M | (m) |
| 2022-03-31 | (m) | $880.50M | $816.10M | (m) | $413.80M | $739.90M | (m) |
| 2021-12-31 | (m) | $938.50M | $1.07B | (m) | $416.90M | $710.10M | (m) |
| 2021-09-30 | (m) | $921.20M | $573.00M | (m) | $372.10M | $732.80M | (m) |
| 2021-06-30 | (m) | $954.60M | $608.10M | (m) | $337.00M | $730.20M | (m) |
| 2021-03-31 | (m) | $943.50M | $696.80M | (m) | $326.00M | $700.70M | (m) |
| 2020-12-31 | (m) | $791.90M | $681.80M | (m) | $335.30M | $692.30M | (m) |
| 2020-09-30 | (m) | $683.20M | $567.10M | (m) | $329.90M | $695.90M | (m) |
| 2020-06-30 | (m) | $749.70M | $746.80M | (m) | $324.50M | $665.40M | (m) |
| 2020-03-31 | (m) | $765.80M | $795.50M | (m) | $325.50M | $625.50M | (m) |
| 2019-12-31 | (m) | $645.60M | $678.30M | (m) | $362.20M | $577.20M | (m) |
| 2019-09-30 | (m) | $643.00M | $296.30M | (m) | $358.80M | $586.70M | (m) |
| 2019-06-30 | (m) | $641.00M | $282.50M | (m) | $348.00M | $594.60M | (m) |
| 2019-03-31 | (m) | $632.70M | $298.80M | (m) | $360.40M | $541.80M | (m) |
| 2018-12-31 | (m) | $599.30M | $322.40M | (m) | $357.20M | $509.60M | (m) |
| 2018-09-30 | (m) | $563.10M | $270.10M | (m) | $323.40M | $518.60M | (m) |
| 2018-06-30 | (m) | $531.50M | $258.70M | (m) | $278.80M | $509.40M | (m) |
| 2018-03-31 | (m) | $558.70M | $283.90M | (m) | $313.60M | $518.00M | (m) |
| 2017-12-31 | $758.50M | $524.50M | $325.00M | $114.20M | $319.30M | $486.20M | 1.45× |
| 2017-09-30 | $699.00M | $513.50M | $263.90M | $165.30M | $269.80M | $515.30M | 1.36× |
| 2017-06-30 | $680.70M | $493.60M | $217.70M | $222.60M | $240.40M | $505.10M | 1.38× |
| 2017-03-31 | $689.90M | $514.90M | $277.50M | $187.00M | $225.40M | $476.40M | 1.34× |
| 2016-12-31 | $744.20M | $524.70M | $342.40M | $157.90M | $243.90M | $440.40M | 1.42× |
| 2016-09-30 | $665.10M | $552.60M | $278.70M | $162.80M | $223.60M | $483.10M | 1.20× |
| 2016-06-30 | $627.30M | $535.10M | $232.50M | $187.90M | $206.90M | $471.00M | 1.17× |
| 2016-03-31 | $653.90M | $541.70M | $209.90M | $210.60M | $233.40M | $460.10M | 1.21× |
| 2015-12-31 | $703.00M | $554.60M | $267.10M | $201.20M | $234.70M | $422.00M | 1.27× |
| 2015-09-30 | $774.60M | $676.10M | $331.00M | $201.30M | $242.30M | $478.30M | 1.15× |
| 2015-06-30 | $733.90M | $652.00M | $320.80M | $172.80M | $240.30M | $486.30M | 1.13× |
| 2015-03-31 | $719.90M | $540.50M | $334.50M | $157.80M | $227.60M | $473.90M | 1.33× |
| 2014-12-31 | $790.70M | $582.70M | $319.50M | $178.00M | $293.20M | $477.40M | 1.36× |
| 2014-09-30 | $711.20M | $610.00M | $329.20M | $113.10M | $268.90M | $566.80M | 1.17× |
| 2014-06-30 | $737.20M | $628.50M | $389.80M | $67.80M | $279.60M | $612.10M | 1.17× |
| 2014-03-31 | (m) | $671.10M | $454.00M | (m) | $295.00M | $620.50M | (m) |
| 2013-12-31 | (m) | $648.60M | $438.70M | (m) | $307.60M | $589.80M | (m) |
| 2013-09-30 | (m) | $646.80M | $306.80M | (m) | $297.70M | $632.00M | (m) |
| 2013-06-30 | (m) | $602.80M | $250.90M | (m) | $300.50M | $601.80M | (m) |
| 2013-03-31 | (m) | $643.20M | $269.40M | (m) | $273.40M | $621.70M | (m) |
| 2012-12-31 | (m) | $681.80M | $310.60M | (m) | $289.30M | $611.50M | (m) |
| 2012-09-30 | (m) | $686.50M | $242.10M | (m) | $264.80M | $632.80M | (m) |
| 2012-06-30 | (m) | $751.90M | $240.30M | (m) | $248.80M | $620.30M | (m) |
| 2012-03-31 | (m) | $771.50M | $229.50M | (m) | $261.80M | $648.00M | (m) |
| 2011-12-31 | (m) | $755.80M | $246.00M | (m) | $282.80M | $576.20M | (m) |
| 2011-09-30 | (m) | $919.50M | $195.80M | (m) | $271.10M | $601.40M | (m) |
| 2011-06-30 | (m) | $901.70M | $169.80M | (m) | $273.70M | $618.70M | (m) |
| 2011-03-31 | (m) | $871.30M | $193.30M | (m) | $250.50M | $571.60M | (m) |
| 2010-12-31 | (m) | $831.50M | $230.40M | (m) | $232.90M | $511.00M | (m) |
| 2010-09-30 | (m) | (m) | $188.00M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $187.60M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $203.10M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $207.10M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $166.20M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |